US009408841B2

(12) **United States Patent**
Teow

(10) **Patent No.: US 9,408,841 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **COMPOSITION COMPRISING HEPATIC THERAPEUTIC ACTIVE FOR TREATING LIVER DISEASES, CERTAIN CANCERS AND LIVER HEALTH MAINTENANCE**

(71) Applicant: **Heptiva LLC**, Rutherford, NJ (US)

(72) Inventor: **Vincent I. Teow**, Rutherford, NJ (US)

(73) Assignee: **Heptiva LLC**, Rutherford, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 153 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/093,111**

(22) Filed: **Nov. 29, 2013**

(65) **Prior Publication Data**

US 2014/0088137 A1 Mar. 27, 2014

Related U.S. Application Data

(62) Division of application No. 13/006,457, filed on Jan. 14, 2011, now Pat. No. 8,618,125.

(51) **Int. Cl.**

A01N 43/42	(2006.01)
A61K 31/44	(2006.01)
A01N 43/82	(2006.01)
A61K 31/41	(2006.01)
A01N 43/16	(2006.01)
A61K 31/35	(2006.01)
A61K 31/473	(2006.01)
A61K 31/355	(2006.01)
A61K 31/277	(2006.01)
A61K 31/352	(2006.01)
A61K 31/382	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/473*** (2013.01); ***A61K 31/277*** (2013.01); ***A61K 31/352*** (2013.01); ***A61K 31/355*** (2013.01); ***A61K 31/382*** (2013.01)

(58) **Field of Classification Search**

USPC 514/297, 453

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,101,558	A	7/1978	Vacek et al.
5,650,386	A	7/1997	Leone-Bay et al.
5,837,257	A	11/1998	Tsai et al.
5,916,984	A	6/1999	Bearson et al.
5,965,121	A	10/1999	Leone-Bay et al.
5,989,556	A	11/1999	Tsai et al.
6,136,316	A	10/2000	Mehrotra et al.
6,403,636	B1	6/2002	Reutrakul et al.
6,455,078	B1	9/2002	Wu
7,078,064	B2	7/2006	Zabrecky
7,126,011	B2	10/2006	Berg
7,160,896	B2	1/2007	Neidle et al.
7,435,755	B2	10/2008	Knopleva et al.
8,618,125	B2	12/2013	Teow
2005/0142222	A1	6/2005	Pan et al.
2006/0110479	A1	5/2006	Mitra et al.
2007/0167441	A1	7/2007	Halbrook et al.
2010/0009970	A1	1/2010	Johansen et al.
2010/0048911	A1	2/2010	Jiang et al.
2010/0074975	A1	3/2010	Eum et al.
2010/0260875	A1	10/2010	Mitra et al.

FOREIGN PATENT DOCUMENTS

WO	WO 94/05276	3/1994
WO	WO 99/33827	8/1999
WO	WO 2010/047633	4/2010

OTHER PUBLICATIONS

Previsani et al., "Hepatitis B," Dept. of Communicable Diseases Surveillance Response, World Health Organization (2002) at p. 6.

Previsani et al., "Hepatitis C," Dept. of Communicable Diseases Surveillance Response, World Health Organization (2002) at pp. 3 and 9.

Zhao et al., "Synthesis of Xanthones, Thioxanthones and Acridones by the Coupling of Arynes and Substituted Benzoates," J. Org. Chem. 72(2): 583-88 (2007).

Laphookhieo et al., "Cytotoxic and Antimalarial Prenylated Xanthones from Cratoxylum cochinchinense," Chem. Pharm. Bull. 54(5): 745-47 (2006).

Honda et al., "Design and Synthesis of 2-Cyano-3,12-Dioxoolean-1,9-Dien-28-Oic Acid, et al," Bioorg. Med. Chem. Lett., 8:2711-2714, (1998).

Honda et al., "Synthetic Oleanane and Ursane Triterpenoids with Modified Rings A and C et al.," J. Med. Chem., 43:4233-4246 (2000).

Honda et al., "A Novel Dicyanotriterpenoid, 2-Cyano-3,12-Dioxooleana-1,9 (11)-Dien-28-onitrile et al.," Bioorg. Med. Chem. Lett., 12:1027-103, (2002).

Kress et al., "Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model et al.," PLoS one (6):e559 (Jun. 2007).

Lavhale et al., "A Novel Triterpenoid Isolated from the Root Bark of Ailanthus excelsa Roxb (Tree of Heaven), et al.," PLoS one 4(4):e5365 (Apr. 2009).

Suh et al, "A Novel Synthetic Oleanane Triterpenoid, Activity Differentiating, Antiproliferative, and Anti-Inflammatory et al.," Cancer Res. 59:336-341 (1999).

Allen et al., "Acridone," Org. Syn. 19:6 (1939).

Allen et al., "Acridone," Org. Syn. 2:15 (1943).

Luo et al., "Crystal Structure of the NS3 Protease-Helicase from Dengue Virus" J. Virol. 82(1): 173-83 (2008).

Duffy, "CA 19-9 as a Marker for Gastrointestinal Cancers: a Review," Ann. Clin. Biochem. 35(Pt 3):364-70. (1998).

(Continued)

Primary Examiner — Layla Soroush

(74) *Attorney, Agent, or Firm* — Eric W. Guttag; Eric W. Guttag IP Law Office

(57) **ABSTRACT**

Compositions of hepatic therapeutic actives from one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid compounds. Also, methods for treating various liver diseases or certain cancers with such hepatic therapeutic actives, as well as providing liver health maintenance.

8 Claims, 4 Drawing Sheets